Recce Pharmaceuticals submits clinical trial data for R327G

• Blind data review indicates strong efficacy and safety for R327G in diabetic foot ulcer infections.
• Company shares rose 18.97% following the clinical trial review announcement.
• Independent committee recommendations are slated for release as soon as mid-November.

Recce Pharmaceuticals (ASX:RCE) submitted blinded data from 75 patients to an independent committee to evaluate its topical gel treatment for diabetic foot ulcer infections.

The submission marks a transition to unblinding the data to compare patient outcomes against placebo treatments in the ongoing Phase 3 trial.

The secondary details confirm that patient recruitment and dosing remain active, with 90 patients currently enrolled at a rate of 4.5 patients per week.

James Graham, CEO, said, "While Recce remains blinded to treatment allocation, the overall efficacy and safety profile observed to date is encouraging."

The company stated that the trial oversight by the data monitoring committee aims to verify safety and efficacy standards throughout the study.

Following the announcement, the Recce Pharmaceuticals share price was up at $0.34.

The study focuses on evaluating the synthetic anti-infective treatment across clinical sites in Indonesia.

The ongoing study aims to address treatment challenges associated with drug-resistant bacterial infections.